NASDAQ 100 % ()
FTSE 100 % ()
DOLLAR INDEX % ()
BTC/USD % ()
EUR/USD % ()
GBP/USD % ()
GOLD % ()
SILVER % ()
CRUDE OIL % ()

ABBV

AbbVie Inc. New York Stock Exchange
$111.24
Open: $0.00 High: $0.00 Low: $0.00 Close: $0.00
Range: 0 - 0
Volume: 0
Market: Closed
Powered by Finage Stock APIDelayed data
ABBV
AbbVie Inc. 1 North Waukegan Road North Chicago IL, 60064-6400 http://www.abbvie.com
AbbVie Inc is a biopharmaceutical company that discovers, develops, manufactures and sells a range of pharmaceutical products for treating chronic autoimmune diseases, virology and neurological disorders.
  • CEO: Richard A. Gonzalez
  • Employees: 30,000
  • Sector: Healthcare
  • Industry: Drug Manufacturers
ABBV News
Latest news about the ABBV
  • 7 Dividend Aristocrats That Will Outlive Us All

    Most long-term investors love passive income stocks. Therefore, today we introduce seven “Dividend Aristocrats,” or businesses that have increased the base dividend every year for the past 25 years. According to metrics from S&P Global (NYSE:SPGI), “Since 1926, dividends have contributed to approximately one-third of total return while capital appreciations have contributed two-thirds. Therefore, both sustainable dividend income and capital appreciation potential are important to total return expectations.” Over the past year, the S&P 500 Dividend Aristocrats Index has returned over 6%. By comparison, the Dow Jones Industrial Average (DJIA) has increased by 5%.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Solid businesses with wide moats tend to be able to generate stable revenues and strong cash flows in most years, even in volatile times or recessions. In fact, many such firms end up gaining market share at the expense of weaker businesses that might simply fight to stay alive during economically tough times. Meanwhile, companies that consistently grow dividends are in effect saying that they are committed to sharing the success of the business with stockholders. With that information, here are seven Dividend Aristocrats that deserve your attention in 2021: 7 Airline Stocks Being Fueled by Vaccine News AbbVie (NYSE:ABBV) Albemarle (NYSE:ALB) Automatic Data Processing (NASDAQ:ADP) Chubb (NYSE:CB) Emerson Electric (NYSE:EMR) ProShares S&P 500 Dividend Aristocrats ETF (BACS:NOBL) Sysco (NYSE:SYY) Dividend Aristocrats: AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com 52-week range: $62.55 – $113.41 1-year price change: Up 23.82% Dividend yield: 4.71% Illinois-based biopharma group AbbVie is our first Dividend Aristocrat. It has numerous research and development (R&D) centers and manufacturing facilities globally. Several of its therapeutic areas include eye care, gastroenterology, immunology, neuroscience, oncology, rheumatology, virology, and women’s health. In addition, its Allergan Aesthetics portfolio includes products, such as Botox Cosmetics, fillers, and implants. The last quarterly report showed non-GAAP adjusted net revenues of $12.882 billion, an increase of 4.1% year-over-year (YoY). Net earnings of $2.31 billion meant an increase of 22.5% YoY. Adjusted diluted EPS was $2.83, up 21% YoY. Cash and equivalents stood at $7.89 billion. CEO Richard A. Gonzalez cited, “Results from key growth products – including Skyrizi, Rinvoq and Ubrelvy – continue to track ahead of our expectations, our aesthetics portfolio is demonstrating a strong V-shaped recovery, our hematologic-oncology franchise is delivering double-digit growth and we’re advancing numerous attractive late-stage pipeline programs.” The company has in-demand therapies and products that contribute to revenue growth. AbbVie’s pipeline also deserves attention. I’d regard any drop in price as an opportunity to buy the shares. Albemarle (ALB) Source: IgorGolovniov/Shutterstock.com 52-week range: $48.89 – $187.25 1-year price change: Up 124.84% Dividend yield: 0.89% Charlotte, North Carolina-based Albemarle produces specialty chemicals used in a wide range of products manufactured by pharmaceutical companies, agricultural companies, water treatment companies, electronics products manufacturers, refineries, and others. In 2020, Albemarle caught investors’ attention as it is the industry leader in lithium, used to make electric vehicle (EV) batteries. Consumers’ love for EVs translated to a jump in the ALB share price. Investors believe the new administration in Washington will continue to provide tailwinds for the renewable energy sector. Q3 results announced in early November showed net sales of $747 million, down by 15% YoY. Net income was $98.3 million and decreased 36.6%. Adjusted diluted EPS of $1.09 showed a decline of 28.8% YoY. CEO Kent Masters said, “We now expect to realize approximately $80 million of cost savings this year and to reach an annual savings rate of $120 million or more by the end of 2021. We expect these savings to represent a first wave of ongoing operational improvements that will reap notable benefits for the company.” 8 Indian Stocks That Belong on Your International Radar ALB stock’s forward P/E and P/S ratios are 48.39x and 6x, respectively. As a result of the recent run-up in price, the valuation metrics are overstretched. Potential investors could consider investing around $170. Automatic Data Processing (ADP) Source: Shutterstock 52-week range: $103.11 – $182.32 1-year price change: Down 7.87% Dividend yield: 2.31% Roseland, New Jersey-based Automatic Data Processing provides cloud-based human capital management (HCM) solutions such as human resources (HR) payroll, tax, and benefits administration, as well as business outsourcing services. The company tends to generate steady, recurring revenue. However, 2020 has also meant challenges due to job losses stateside, which has meant revenue loss for the group. According to the most recent quarterly metrics, revenues came at $3.5 billion, down by 1% YoY. Adjusted net earnings of $605 million showed an increase of 4%. Adjusted diluted EPS was $1.41 and increased by 5%. CFO Kathleen Winters commented, “Our first quarter results significantly exceeded our expectations across the board… While we still expect to face headwinds over the course of the year, we will continue to look for ways to drive strong performance in both the near and long-term.” Forward P/E and P/S ratios are 27.9x and 4.81x, respectively. Despite the recent decline in price, I believe the shares are still richly valued for the current environment. A potential decline would improve the margin of safety. Emerson Electric (EMR) Source: Shutterstock 52-week range: $37.75 – $84.44 1-year price change: Up 6.29% Dividend yield: 2.44% St Louis, Missouri-based Emerson Electric is a technology and engineering company. The group focuses on Automation Solutions (manufacturing electrical components and providing services and training) and Commercial & Residential Solutions (covering heating, air conditioning, and refrigeration). FY20 Q4 metrics released in early November showed GAAP net sales of $4.6 billion, down 8% YoY. Net earnings were $723 million, up 1% YoY. Adjusted EPS came at $1.10, down 4%. Free cash flow for the quarter was $1.02 billion and increased 2%. CEO David N. Farr commented, “Amidst all the challenges, we exceeded our second quarter reset financial forecast in sales, EBITDA, and cash flow… We also continued to invest and took bold action to build on our innovation and technology footprint of the future, with three strategic acquisitions: American Governor, Open Systems International Inc. and Progea.” 9 Beginner Stocks for First-Time Investors EMR stock’s forward P/E and P/S ratios are 25.5x and 2.99x, respectively. Emerson Electric’s automation division currently has significant exposure to the traditional energy (i.e., oil and gas) industry. However, it is also growing its alternative energy (i.e., clean fuels and renewables) businesses. Any decline below $80, especially toward $75, would offer a good entry point into the engineering group. Chubb (CB) Source: thodonal88 / Shutterstock.com 52-week range: $87.35 – $167.74 1-year price change: Up 1.66% Dividend yield: 2% Chubb is one of the largest publicly traded property and casualty insurance companies worldwide. 2020 has meant challenges for the industry. The pandemic, hurricanes, flooding, flooding, and civil unrest have meant increased insurance claims. However, the company’s operations stood the test of times. The most recent quarterly earnings showed revenue of $9.46 billion, up 4.6% YoY. Net income was $1.19 billion, an increase of 9.4%. Diluted EPS was $2.63, up by 10.5%. Operating cash flow was $3.5 billion. CEO Evan G. Greenberg cited, “With strong and continuously improving underwriting conditions in most all regions of the world, we grew P&C (property and casualty) net premiums written 6.5% in the quarter in constant dollars, comprised of 10.8% growth in our commercial P&C business and a 3.3% decline in consumer lines … we expect to grow our EPS through both revenue growth and improved margins.” The fact that Chubb was able to grow its premiums written in 2020 makes it stand out among insurers. I believe the shares could find a place in most long-term portfolios. ProShares S&P 500 Dividend Aristocrats ETF (NOBL) Source: Shutterstock 52-week range: $48.62 – $81.96 1-year price change: Up 1.31% Dividend yield: 1.25% Expense ratio: 0.35% Our next choice is an exchange-traded fund (ETF), namely the ProShares S&P 500 Dividend Aristocrats ETF. It focuses on the S&P 500 Dividend Aristocrats Index comprised of businesses that have grown dividends for decades, not just for 25 consecutive years. The fund, which started trading in September 2013, has 65 holdings. Total net assets of the fund are around $6.2 billion. As far as sector allocations are concerned, Industrials leads the ETF with 24.03%, followed by Consumer Staples (18.78%), and Materials (13.19%). The top ten names, with approximately equal weights, make up around 20% of net assets. Albemarle, Exxon Mobil (NYSE:XOM), AbbVie, Walgreens Boots Alliance (NASDAQ:WBA) head the roster. 10 Smart Stocks to Buy With $5,000 NOBL returned 6% in the past 52 weeks. I believe any decline in the price of the fund during this earnings season would make it a good buy for long-term portfolios. Sysco (SYY) Source: JHVEPhoto/Shutterstock.com 52-week range: $26 – $84.12 1-year price change: Down 8.58% Dividend yield: 2.35% Houston, Texas-based Sysco sells food products and related equipment to restaurants, health care facilities, hotels, and educational facilities. It has about 57,000 employees in over 300 distribution facilities worldwide. The customer count exceeds 620,000. Needless to say, 2002 was a difficult year as many of those customers had to scale down operations due to the pandemic. Sysco released FY21 Q1 metrics in early November. Sales were $11.8 billion, a decrease of 23.0% YoY. Non-GAAP net earnings were $173.5 million, down by 66.0%. Non-GAAP diluted EPS was 34 cents, a decline of 65.3% CEO Kevin Hourican said, “Although our first quarter 2021 results continue to be impacted by the pandemic, we are pleased with our overall expense management and our ability to produce positive free cash flow and a profitable quarter despite a 23% reduction in sales.” A potential decline toward $70 would offer better long-term value. In the coming quarters, as economies recover and cities and countries go back to normal, Sysco’s operations are likely to recover as well. On the date of publication, Tezcan Gecgil did not have (either directly or indirectly) any positions in the securities mentioned in this article. Tezcan Gecgil has worked in investment management for over two decades in the U.S. and U.K. In addition to formal higher education in the field, she has also completed all 3 levels of the Chartered Market Technician (CMT) examination. Her passion is for options trading based on technical analysis of fundamentally strong companies. She especially enjoys setting up weekly covered calls for income generation. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG Top Stock Picker Reveals His Next 1,000% Winner It doesn’t matter if you have $500 in savings or $5 million. Do this now. The post 7 Dividend Aristocrats That Will Outlive Us All appeared first on InvestorPlace.

    View More →
  • AbbVie (ABBV) Gains But Lags Market: What You Should Know

    In the latest trading session, AbbVie (ABBV) closed at $112.62, marking a +0.39% move from the previous day.

    View More →
  • 8 Quality Dividend Stocks for Durable Growth and Income

    From "Dividend Aristocrats" to special situations, Ben Reynolds -- along with his co-editors Bob Ciura and Nikolaos Sismanis -- provides in-depth research on high-quality stocks through its four top-ranked newsletters. Scale is a critical competitive advantage in the industry. The company's durable competitive advantage -- and shareholder friendliness -- is on display with its long dividend history.

    View More →
  • Top Stock Reports for Novartis, QUALCOMM & Accenture

    Top Stock Reports for Novartis, QUALCOMM & Accenture

    View More →
  • AbbVie Stock Is Trading Near A 3-Year High — Is It Time To Add ABBV Stock?

    AbbVie stock is trading close to a three-year high after the company entered into an agreement that would allow it to buy Cypris Medical, a privately held medical devices company.

    View More →
  • Allergan Aesthetics and Allergan, an AbbVie Company, to Present 16 Neurotoxin Research Abstracts Across Multiple Therapeutic and Cosmetic Indications at the TOXINS 2021 Virtual Conference

    Allergan Aesthetics and Allergan, an AbbVie company (NYSE: ABBV), announced today that scientific and clinical experts in the field of neurotoxins will present results from 16 abstracts spanning pre-clinical and clinical studies evaluating key safety and efficacy of BOTOX® (onabotulinumtoxinA) across multiple therapeutic and cosmetic indications. Data includes long-term immunogenicity rates across 10 therapeutic and aesthetic indications, analyses from the Adult Spasticity International Registry (ASPIRE) study and Cervical Dystonia Patient Registry for BOTOX® Efficacy (CD-PROBE), reviewing adherence to onabotulinumtoxinA treatment in patients with spasticity and efficacy and tolerability in patients with cervical dystonia, respectively. Also to be presented are data on incontinence product use and associated costs in patients with overactive bladder treated with onabotulinumtoxinA. Additionally, results from a randomized controlled clinical trial on the efficacy and safety of three active doses of onabotulinumtoxinA for the treatment of neurogenic detrusor overactivity in children and findings from a study on the safety, pharmacodynamic response and treatment satisfaction, with increasing doses of onabotulinumtoxinA in patients with moderate to severe dynamic glabellar lines will be presented. These data will be presented at the TOXINS 2021 Virtual Conference, organized by The International Neurotoxin Association (INA), January 16-17.

    View More →
  • Best Healthcare Stocks to Buy for 2021

    Real Money contributor Stephen Guilfoyle checks which sector names could perform best over the coming year.

    View More →
  • AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know

    AbbVie (ABBV) closed at $111.63 in the latest trading session, marking a -0.73% move from the prior day.

    View More →
  • AbbVie (ABBV) Inks Deal to Acquire Medical Device Company

    AbbVie (ABBV) signs an agreement to acquire privately held Cypris Medical, including the latter's Xact device which is used for performing face and neck lifts.

    View More →
  • These 3 Value Stocks Are Absurdly Cheap Right Now

    Investors have collectively made some misguided assumptions about the condition these companies are actually in.

    View More →
  • Harpoon Therapeutics Granted Orphan Drug Designation from FDA for HPN217 for Treatment of Multiple Myeloma

    SOUTH SAN FRANCISCO, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for HPN217 for the treatment of multiple myeloma. HPN217, a tri-specific T cell activating recombinant protein construct (TriTAC®) targets B-cell maturation antigen (BCMA), a well-validated antigen expressed on malignant multiple myeloma cells. Harpoon has four drug product candidates in clinical development for the treatment of solid and hematologic malignancies based on its proprietary TriTAC platform. “Orphan Drug Designation for multiple myeloma represents a significant milestone in the development of HPN217 and recognizes its potential to address a significant unmet medical need for the patients suffering from this condition,” said Jerry McMahon, Ph.D., President and Chief Executive of Harpoon Therapeutics. “I am pleased with the clinical progress we are making with this program and we are planning to present interim data from the ongoing Phase 1/2 dose escalation trial later this year.”The FDA's Orphan Drug Designation program provides orphan status to drugs defined as those intended for the safe and effective treatment, diagnosis or prevention of rare diseases that affect fewer than 200,000 people in the United States. Orphan Drug Designation qualifies the sponsor of the drug for certain development incentives, including tax credits for qualified clinical testing, prescription drug user fee exemptions and seven-year marketing exclusivity upon FDA approval.About the Phase 1/2 Trial for HPN217In April 2020, Harpoon announced dosing of the first patient with HPN217 (BCMA TriTAC) in a Phase 1/2 clinical trial focused on relapsed/refractory multiple myeloma (RRMM). HPN217 is covered by a global development and option agreement with AbbVie Inc. (NYSE: ABBV). Dose escalation for HPN217 in the Phase 1/2 clinical trial is progressing rapidly. HPN217 has been well tolerated, and no DLTs had been observed as of the most recent December 1, 2020 data cutoff date. A presentation of interim data is anticipated in 2021, with initiation of a dose expansion cohort in the second half of 2021.For additional information about the trial, please visit clinicaltrials.gov using the identifier NCT04184050.About Harpoon TherapeuticsHarpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. HPN424 targets PSMA and is in a Phase 1/2a trial for metastatic castration-resistant prostate cancer. HPN536 targets mesothelin and is in a Phase 1/2a trial for cancers expressing mesothelin, initially focused on ovarian and pancreatic cancers. HPN217 targets BCMA and is in a Phase 1/2 trial for relapsed, refractory multiple myeloma. HPN328 targets DLL3 and is in a Phase 1/2 trial for small cell lung cancer and other DLL3-associated tumors. Harpoon has also developed a proprietary ProTriTAC™ platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. For additional information about Harpoon Therapeutics, please visit www.harpoontx.com.Cautionary Note on Forward-looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “target,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Harpoon Therapeutics’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause Harpoon Therapeutics’ clinical development programs, future results or performance to differ significantly from those expressed or implied by the forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the progress, timing, scope and anticipated results of clinical trials, the timing of the presentation of data, the association of data with potential treatment outcomes, the development and advancement of product candidates, the timing of development milestones for product candidates, and the anticipated potential impacts to Harpoon Therapeutics’ business from the ongoing COVID-19 pandemic. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during clinical studies, clinical trial site activation or enrollment rates that are lower than expected, unanticipated or greater than anticipated impacts or delays due to COVID-19, changes in expected or existing competition, changes in the regulatory environment, the uncertainties and timing of the regulatory approval process, and unexpected litigation or other disputes. Other factors that may cause Harpoon Therapeutics’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Harpoon Therapeutics’ filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections contained therein. Except as required by law, Harpoon Therapeutics assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.Contacts:Harpoon Therapeutics, Inc. Georgia Erbez Chief Financial Officer 650-443-7400 media@harpoontx.comWestwicke ICR Robert H. Uhl Managing Director 858-356-5932 robert.uhl@westwicke.com

    View More →
  • 3 Dividend Aristocrats to Buy Right Now

    Investors want to be able to count on dividend payments that are like clockwork. It's even better when that consistency isn't just related to paying dividends but also includes dividend increases. Dividend Aristocrats include only S&P 500 members that have boosted their dividends for at least 25 consecutive years.

    View More →
  • AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know

    AbbVie (ABBV) closed at $109.78 in the latest trading session, marking a +0.7% move from the prior day.

    View More →
  • Allergan Aesthetics Enters Into Option to Acquire Cypris Medical

    Today Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced that it has entered into a warrant agreement with Cypris Medical, a privately held, medical device company based in Chicago. Following the completion of a clinical trial to be initiated in 2021, Allergan Aesthetics will have the right to exercise an option to acquire Cypris Medical, including the company's Xact device. The planned clinical trial will evaluate the safety and effectiveness of Xact in treating midface descent as well as for neck lifts.

    View More →
  • AbbVie to Host Fourth-Quarter and Full-Year 2020 Earnings Conference Call

    AbbVie (NYSE: ABBV) will announce its fourth-quarter and full-year 2020 financial results on Wednesday, February 3, 2021, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website investors.abbvie.com. An archived edition of the session will be available later that day.

    View More →
  • Dragonfly Therapeutics Announces AbbVie Opt-In of TriNKET™ Immunotherapy Drug Candidate

    Dragonfly to receive payment for the first Opt-In from AbbVie as part of a multi-target collaboration launched just over 1 year ago.WALTHAM, Mass.

    View More →
  • AbbVie (ABBV) Gains As Market Dips: What You Should Know

    AbbVie (ABBV) closed at $109.02 in the latest trading session, marking a +1.63% move from the prior day.

    View More →
  • How Safe Is AbbVie's Dividend?

    It's human nature to worry. There's a reason why old adages such as "all good things must come to an end" remain widely used -- we tend to expect something to go wrong. For income-seeking investors, everything has gone right with AbbVie (NYSE: ABBV) for a long time.

    View More →
  • 3 Stocks That Are Absurdly Cheap Right Now

    Three ridiculously cheap stocks that you should consider buying right now are AbbVie (NYSE: ABBV), Lumen Technologies (NYSE: LUMN), and Dell (NYSE: DELL). AbbVie is a top healthcare stock that got a whole lot bigger in 2019 after closing on its $63 billion deal to acquire Botox-maker Allergan. Although the immunosuppressant Humira remains the company's top-selling drug, AbbVie will lose patent protection on it in 2023.

    View More →
  • AbbVie Inc. (NYSE:ABBV) Pays A US$1.30 Dividend In Just Four Days

    AbbVie Inc. ( NYSE:ABBV ) stock is about to trade ex-dividend in four days. This means that investors who purchase...

    View More →